Probiotic Group Raises €2.5m, Opens Unit In House Of BioHealth

The company employs about twenty employees in the Grand Duchy of Luxembourg (Photo © Probiotic Group)

Luxembourg scaleup Probiotic Group has secured €2.5m from Belgian funds after closing a Series A funding round. 

The firm, which specialises in biotechnology in relation to microbiomes, is expected to use the finance to accelerate its R&D activities in Luxembourg. 

“We invested largely in the House of BioHealth where, by the end of the summer, we’ll be opening a new unit in the Red/Orange building as well as increasing headcounts to accelerate our growth in terms of revenue,” CCO Martin Schoonbroodt told Silicon Luxembourg. 

Probiotic Group was founded in 2014  by Belgian orthodontist Martin M. G. Schoonbroodt with the mission to develop probiotic care and sustainable and effective cleaning products. Its products offer an alternative to traditional cleansers in the way they combat microbial imbalances while also optimising different biological environments. 

“After several years of fundamental and applied research around bacteria, Probiotic Group has developed a range of sustainable products based on the principle of circular economy that respect humans, animals and the environment in three segments (cleaning, animals, cosmetics) under own brand (Provilan) and private label B2C brands,” the firm said in a press release. 

Probiotic Group, which employs around 20 people in Luxembourg, is currently in talks with multinationals in Europe and the US for supply contracts and co-developments. 

Schoonbroodt told Silicon Luxembourg that the firm’s priority is to finalise development of a cosmetic rinse-off line and release its first biocidal product, DENAA+ Zero.

According to the CCO, this product “is based on a natural active substance enabling disinfection with respect to nature.” 

In 2019 and 2020, Probiotic Group won multiple innovation awards in Germany. Schoonbroodt said: This provided us a huge spotlight. Therefore and among other things, our company is talking to the biggest corporations to supply our biotechnologies “made in Luxembourg” in the near future.”

The company employs about twenty employees in the Grand Duchy of Luxembourg spread over a production site and a research site working in close collaboration with the Luxembourg Institute of Science & Technology (LIST) and the University of Luxembourg (LCSB).

It is co-run by the founder’s son, Martin Schoonbroodt, and Paul Mauhin.

Related Posts